

Microba to Present at International Microbiome Conference

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce Global Business Development lead, Mark Parker, will present at the 3rd International World of Microbiome Conference in Vienna on Saturday 30 April from 10:20AM CET (6:20PM AEST). Microba is continuing to attract new business opportunities in Europe through an increased presence following the COVID period. A copy of the presentation is attached to this announcement.

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.



Microba's Discovery Platform

A unique dataset for discovery


World of Microbiome | Vienna

Mark Parker

Global Business Development, Microba Life Sciences

April 2022 | Authorised for release by the CEO and Chairman


There is unequivocal evidence demonstrating the **human gut microbiome acts systemically** and is a critical factor in disease



Deficient analysis and fragmented datasets are limiting progress

- Incomplete measurement of gut microbiome communities
- High error rates with existing tools
- Underpowered datasets leading to unclear results
- Resistance to culture impedes efforts to assess therapeutic efficacy of priority microbes

Microba's **data-driven discovery** interrogates the novel microbiome



Microba's leading metagenomics analysis platform measures the microbiome with **unparalleled performance**



Microba Community Profiler

Metagenomic mapping technology delivering leading microbiome measurement when combined with Microba's Genome Database



Microba Genome Database


World leading, expertly curated microbial genome reference database of microbial genomes to deliver unmatched detection coverage of the human microbiome

Precision

We have world leading specificity and sensitivity


Superior coverage

*We classify up to **95%** per sample¹*



Data generated by Microba Life Sciences


In a real faecal sample, our analysis shows how much can be missed without precise metagenomic analysis




**67% of community
diversity uncultured**

**33% of community
Cultured**

Using precision microbiome analysis to generate
a **globally unique dataset** to power microbiome discovery



Human first, data-driven approach to microbiome discovery & development



Inflammatory Bowel Disease Program

Demonstrating rapid translation from data to first in human

CANDIDATE SELECTION PROCESS

4,784 Bacteria observed
in Microba dataset

Many bacteria
differentially abundant in
health vs IBD

Bacteria
prioritised based
on signal strength

12 isolated using
proprietary isolation
techniques

In vitro & *in vivo* testing
completed on 10 leads

3 Lead candidates
selected based on
efficacy
& safety profile


Lead candidate selected
& manufactured for
Phase I

18 months


Microba
Today
Is significantly
progressed

Leads show strong *in vitro* therapeutic activity of cell migration and immune suppression - further elucidating mechanism of action


Leads promotes epithelial cell migration – a key process underpinning effective wound repair and mucosal healing



Leads suppresses IL-23 mediated STAT3 activation – a crucial pathway in the uncontrolled intestinal inflammatory process of IBD




Advanced artificial intelligence and machine learning capabilities can discover strong signals from **complex datasets**




Identifying microbiome leads using a big data approach and multiple methods

160 species significantly associated with anxiety (FDR < 0.05)



Machine learning methods improve confidence in selected signals



Opportunities for partnership to drive new discovery

Analysis Platform

End-to-end solution for
precise and comprehensive
microbiome analysis

- Clinical trial support
- End-to-end research services, including sample collection, bioinformatics and statistical analysis, and results interpretation

Discovery Platform

A **globally unique data resource**
and advanced capabilities in
data mining and AI

- Identify microbial biomarkers associated with health, disease, environment and lifestyle
- Discover microbiome directed interventions and probiotic leads

Therapeutic Platform

Human first, data-driven
lead identification and
proprietary **isolation** methods

- Develop novel microbiome derived drugs, including live microbial drugs and bioactive molecules

Access **world-leading technology and expertise** in microbiome analysis at any stage of your research.

Contact



Mark Parker

Global Business Development
Mark.parker@microba.com

Head Office

Level 10, 324 Queen Street,
Brisbane, QLD Australia

Laboratory

Princess Alexandra Hospital,
Brisbane, QLD Australia

Acknowledgements



Prof Gene Tyson
Co-Founder,
Non-Executive Director



Prof Phil Hugenholtz
Co-Founder, Chair of
Scientific Advisory Board



Dr Páraic Ó Cuív
VP Drug Discovery



Dr Nicola Angel
Laboratory Director



Blake Wills
Advisor, Strategic Alliances



Dr Luke Holtham
Chief Executive Officer



Dr Kylie Ellis
Head of Research
Partnerships



Prof Ian Frazer
Director and Chair Medical
Advisory Board



Dr Martha Cooper
Data Scientist



Dr Joel Boyd
Bioinformatics
Researcher



Dr Alena Pribyl
Senior Scientist and
Research Officer



Dr Michael Nissen
Computational
Immunologist



Alexander Hasson
Scientist AI and Data-
Mining



Mark Parker
Global Business
Development



Dr Areej Alshiekh
Bioinformatician



Dr David Wood
Head of Bioinformatics
Operations



Tim Lamberton
Bioinformatics
Researcher



Charlotte Vivian
Research Associate



Dr Andrea Rabellino
Senior Scientist
Cell Biology



Dr Joyce Chou
Scientist Microbiology



Dr Annika Krueger
Scientist Cell Biology



Dr Donovan Parks
Bioinformatic
Consultant



A/Prof Jake Begun
Medical Advisory Board,
IBD Advisory Panel



Prof Maria Abreu
IBD Advisory Board



Assoc Prof Paul Griffin
Medical Advisory Board